Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

UFS researcher engineers metal surfaces
2015-03-03

Shaun Cronjé, a PhD student, in a surface characterisation laboratory at the UFS.

It is well known that the surface of a component is much more vulnerable to damage than the interior, and that surface-originated degradation such as wear, corrosion, and fracture will eventually destroy the component.

“Engineering the surface, based on scientific knowledge, is essential to control these damaging processes. It also creates electronic and geometric structures on the surface which opens up a world of new devices, especially considering the properties on the nano-length scale,” said Prof Wiets Roos from the Department of Physics at the University of the Free State (UFS).

At elevated temperatures, atoms are more mobile and can migrate to grain boundaries and surfaces, which have a major influence on material properties. The redistribution of solute atoms between the surface and the bulk of the material is known as segregation. Knowing the behaviour of segregation at the surface/environment interface can be very useful in the development of new materials. As an example materials can be improved higher efficiency and lower fuel consumption, thus reducing environmental pollution.

The main aims of Prof Roos’s research are to understand surface segregation, use it as a tool, and contribute to the various surface engineering fields.

The surface characterisation laboratories at the UFS are well equipped to do high temperature segregation measurements, and have already proven a success, not only in the ability to prepare the specimens for characterisation, but also in developing models and procedures to quantify the segregation parameters.

The most recent results have demonstrated the importance of taking evaporation into account during quantification.” This has laid the foundation for future studies by installing the necessary hardware in a surface characterisation spectrometer, establishing experimental protocols, and improving an existing model (developed in this laboratory) for simulating segregation profiles,” said Prof Roos.

Segregation parameters allow the researcher to predict and utilise the surface concentration behaviour as a function of temperature and time. “This not only contributes to fields involving corrosion, oxidation, sintering, wear, chemical poisoning, powder metallurgy, and lubrication but adds to the development of self-healing devices,” said Prof Roos.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept